<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM13252</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-13252</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Сахарный диабет 1 типа у детей: впереди взрослая жизнь</article-title><trans-title-group xml:lang="en"><trans-title>Type 1 diabetes in children: adulthood ahead</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4316-8546</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лаптев</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Laptev</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаптев Дмитрий Никитич, д.м.н.</p><p>WoS Researcher ID: O-1826-2013; Scopus Author ID: 24341083800</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Dmitry N. Laptev, MD, PhD</p><p>WoS Researcher ID: O-1826-2013; Scopus Author ID: 24341083800</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">laptevdn@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>01</month><year>2025</year></pub-date><volume>28</volume><issue>1</issue><fpage>18</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лаптев Д.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Лаптев Д.Н.</copyright-holder><copyright-holder xml:lang="en">Laptev D.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/13252">https://www.dia-endojournals.ru/jour/article/view/13252</self-uri><abstract><p>Сахарный диабет 1 типа (СД1) в детском возрасте является одной из острейших социальных и медицинских проблем, учитывая растущую заболеваемость и негативное влияние на продолжительность и качество жизни. Возникновение заболевания в детском возрасте приводит к значительному снижению продолжительности жизни у пациентов с СД1, что во многом связано с микро- и макрососудистыми осложнениями, и фундамент этих патологических процессов формируется именно в детстве вследствие неоптимального контроля заболевания. Так, данные регистров указывают, что меньше половины детей с СД1 достигает целевого гликемического контроля, а в подростковом возрасте наблюдается наихудший гликемический контроль среди всех возрастных периодов.</p><p>В последние годы у детей с СД1 стали гораздо активнее использоваться современные инструменты лечения: помповая инсулинотерапия, непрерывный мониторинг глюкозы и системы автоматического введения инсулина, что стало возможным благодаря повышению их доступности, удобства и доказанной эффективности. Эти технологии позволяют не только уменьшить бремя заболевания, но и повысить эффективность лечения СД1 у детей и, следовательно, уменьшить риски диабетических осложнений для сохранения здоровья перед предстоящей взрослой жизнью.</p></abstract><trans-abstract xml:lang="en"><p>Type 1 diabetes mellitus (T1DM) in childhood is one of the most important social and medical problems, given the growing incidence and negative impact on the duration and quality of life. The onset of the disease in childhood associated with significantly reduced life expectancy, largely due to micro- and macrovascular complications, and background pathological processes may occur from the T1DM onset due to suboptimal glucose control. Large registers data indicate that less than half of children with T1DM achieve target glycemic control, and adolescence is characterized by the worst glycemic control among all age groups. In recent years, modern treatment tools have been widely adopted in children with T1DM: insulin pumps, continuous glucose monitoring and automatic insulin delivery systems, which has become possible due to their increased availability, convenience and proven effectiveness. These technologies not only reduce the burden of the disease, but also improve the effectiveness of treatment of T1DM in children, consequently reducing the risks of diabetic complications protecting the health for the upcoming adult life.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>непрерывный мониторинг глюкозы</kwd><kwd>инсулиновая помпа</kwd><kwd>система автоматического введения инсулина</kwd><kwd>искусственный интеллект</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>continuous glucose monitoring</kwd><kwd>insulin pump</kwd><kwd>automatic insulin delivery system</kwd><kwd>artificial intelligence</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gregory GA, Robinson TM, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-760. doi: https://doi.org/10.1016/S2213-8587(22)00218-2</mixed-citation><mixed-citation xml:lang="en">Gregory GA, Robinson TM, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-760. doi: https://doi.org/10.1016/S2213-8587(22)00218-2</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Безлепкина О.В., Шешко Е.Л., и др. Основные эпидемиологические показатели сахарного диабета 1 типа у детей в Российской Федерации за 2014–2023 годы // Проблемы эндокринологии. — 2024. — Т.70. — №5. — С. 76–83. doi: https://doi.org/10.14341/probl13515</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Bezlepkina OB, Sheshko EL, et al. Main epidemiological indicators of type 1 diabetes mellitus in children in the Russian Federation for 2014–2023. Problems of Endocrinology. 2024;70(5):76-83. (In Russ.) doi: https://doi.org/10.14341/probl13515</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Петеркова В.А., и др. Сахарный диабет у детей и подростков по данным Федерального регистра Российской Федерации: динамика основных эпидемиологических характеристик за 2013–2016 гг. // Сахарный диабет. — 2017. — Т.20. — №6. — С. 392–402. doi: https://doi.org/10.14341/DM9460</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Peterkova VA, et al. Diabetes mellitus in children and adolescents according to the Federal diabetes registry in the Russian Federation: dynamics of major epidemiological characteristics for 2013–2016. Diabetes mellitus. 2017;20(6):392-402. (In Russ.) doi: https://doi.org/10.14341/DM9460</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hermann JM, Miller KM, Hofer SE, et al. The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabet Med. 2020;37(5):848-855. doi: https://doi.org/10.1111/dme.14148</mixed-citation><mixed-citation xml:lang="en">Hermann JM, Miller KM, Hofer SE, et al. The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabet Med. 2020;37(5):848-855. doi: https://doi.org/10.1111/dme.14148</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gerhardsson P, Schwandt A, Witsch M, et al. The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes. Diabetes Technol Ther. 2021;23(7):491-499. doi: https://doi.org/10.1089/dia.2020.0618</mixed-citation><mixed-citation xml:lang="en">Gerhardsson P, Schwandt A, Witsch M, et al. The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes. Diabetes Technol Ther. 2021;23(7):491-499. doi: https://doi.org/10.1089/dia.2020.0618</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gandhi K, Ebekozien O, Noor N, et al. Insulin Pump Utilization in 2017-2021 for More Than 22,000 Children and Adults With Type 1 Diabetes: A Multicenter Observational Study. Clin Diabetes. 2024;42(1):56-64. doi: https://doi.org/10.2337/cd23-0055</mixed-citation><mixed-citation xml:lang="en">Gandhi K, Ebekozien O, Noor N, et al. Insulin Pump Utilization in 2017-2021 for More Than 22,000 Children and Adults With Type 1 Diabetes: A Multicenter Observational Study. Clin Diabetes. 2024;42(1):56-64. doi: https://doi.org/10.2337/cd23-0055</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ross PL, Milburn J, Reith DM, Wiltshire E, Wheeler BJ. Clinical review: insulin pump-associated adverse events in adults and children. Acta Diabetol. 2015;52(6):1017-1024. doi: https://doi.org/10.1007/s00592-015-0784-2</mixed-citation><mixed-citation xml:lang="en">Ross PL, Milburn J, Reith DM, Wiltshire E, Wheeler BJ. Clinical review: insulin pump-associated adverse events in adults and children. Acta Diabetol. 2015;52(6):1017-1024. doi: https://doi.org/10.1007/s00592-015-0784-2</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mecklenburg RS, Benson EA, Benson JW Jr, et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA. 1984;252(23):3265-3269. doi: https://doi.org/10.1001/jama.1984.03350230025026</mixed-citation><mixed-citation xml:lang="en">Mecklenburg RS, Benson EA, Benson JW Jr, et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA. 1984;252(23):3265-3269. doi: https://doi.org/10.1001/jama.1984.03350230025026</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wheeler BJ, Donaghue KC, Heels K, Ambler GR. Family perceptions of insulin pump adverse events in children and adolescents. Diabetes Technol Ther. 2014;16(4):204-207. doi: https://doi.org/10.1089/dia.2013.0315</mixed-citation><mixed-citation xml:lang="en">Wheeler BJ, Donaghue KC, Heels K, Ambler GR. Family perceptions of insulin pump adverse events in children and adolescents. Diabetes Technol Ther. 2014;16(4):204-207. doi: https://doi.org/10.1089/dia.2013.0315</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wheeler BJ, Heels K, Donaghue KC, Reith DM, Ambler GR. Insulin pump-associated adverse events in children and adolescents--a prospective study. Diabetes Technol Ther. 2014;16(9):558-562. doi: https://doi.org/10.1089/dia.2013.0388</mixed-citation><mixed-citation xml:lang="en">Wheeler BJ, Heels K, Donaghue KC, Reith DM, Ambler GR. Insulin pump-associated adverse events in children and adolescents--a prospective study. Diabetes Technol Ther. 2014;16(9):558-562. doi: https://doi.org/10.1089/dia.2013.0388</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia. 2013;56(11):2392-2400. doi: https://doi.org/10.1007/s00125-013-3007-9</mixed-citation><mixed-citation xml:lang="en">Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia. 2013;56(11):2392-2400. doi: https://doi.org/10.1007/s00125-013-3007-9</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Benkhadra K, Alahdab F, Tamhane SU, McCoy RG, Prokop LJ, Murad MH. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2017;55(1):77-84. doi: https://doi.org/10.1007/s12020-016-1039-x</mixed-citation><mixed-citation xml:lang="en">Benkhadra K, Alahdab F, Tamhane SU, McCoy RG, Prokop LJ, Murad MH. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2017;55(1):77-84. doi: https://doi.org/10.1007/s12020-016-1039-x</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sherr JL, Schoelwer M, Dos Santos TJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatr Diabetes. 2022;23(8):1406-1431. doi: https://doi.org/10.1111/pedi.13421</mixed-citation><mixed-citation xml:lang="en">Sherr JL, Schoelwer M, Dos Santos TJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatr Diabetes. 2022;23(8):1406-1431. doi: https://doi.org/10.1111/pedi.13421</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26(4):1142-1146. doi: https://doi.org/10.2337/diacare.26.4.1142</mixed-citation><mixed-citation xml:lang="en">Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26(4):1142-1146. doi: https://doi.org/10.2337/diacare.26.4.1142</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Alsaleh FM, Smith FJ, Keady S, Taylor KM. Insulin pumps: from inception to the present and toward the future. J Clin Pharm Ther. 2010;35(2):127-138. doi: https://doi.org/10.1111/j.1365-2710.2009.01048.x</mixed-citation><mixed-citation xml:lang="en">Alsaleh FM, Smith FJ, Keady S, Taylor KM. Insulin pumps: from inception to the present and toward the future. J Clin Pharm Ther. 2010;35(2):127-138. doi: https://doi.org/10.1111/j.1365-2710.2009.01048.x</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics. 2006;117(6):2126-2131. doi: https://doi.org/10.1542/peds.2005-2621</mixed-citation><mixed-citation xml:lang="en">Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics. 2006;117(6):2126-2131. doi: https://doi.org/10.1542/peds.2005-2621</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Переверзева С.В., Емельянов А.О., и др. Мониторинг применения помповой инсулинотерапии у детей, подростков и молодых пациентов с сахарным диабетом 1 типа в Российской Федерации // Проблемы эндокринологии. — 2018. — Т.64. — №2. — С.85-92. doi: https://doi.org/10.14341/probl8756</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Pereverzeva SV, Emelyanov AO, et al. Monitoring of insulin pump therapy in children, adolescents, and young adults with type 1 diabetes mellitus in the Russian Federation. Problems of Endocrinology. 2018;64(2):85-92. (In Russ.) doi: https://doi.org/10.14341/probl8756</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Емельянов А.О., Медведева Е.Д., и др. Длительный гликемический контроль и факторы, ассоциированные с ответом на помповую инсулинотерапию у детей // Сахарный диабет. — 2021. — Т.24. — №2. — С.122-132. doi: https://doi.org/10.14341/DM12530</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Emelyanov AO, Medvedeva ED, et al. Long-term glycemic control and factors, associated with response to pump insulin therapy in children. Diabetes mellitus. 2021;24(2):122-132. (In Russ.) doi: https://doi.org/10.14341/DM12530</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765-774. doi: https://doi.org/10.1111/j.1464-5491.2008.02486.x</mixed-citation><mixed-citation xml:lang="en">Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765-774. doi: https://doi.org/10.1111/j.1464-5491.2008.02486.x</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Pańkowska E, Błazik M, Dziechciarz P, et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10(1):52-58. doi: https://doi.org/10.1111/j.1399-5448.2008.00440.x</mixed-citation><mixed-citation xml:lang="en">Pańkowska E, Błazik M, Dziechciarz P, et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10(1):52-58. doi: https://doi.org/10.1111/j.1399-5448.2008.00440.x</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sherr JL, Hermann JM, Campbell F, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87-91. doi: https://doi.org/10.1007/s00125-015-3790-6</mixed-citation><mixed-citation xml:lang="en">Sherr JL, Hermann JM, Campbell F, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87-91. doi: https://doi.org/10.1007/s00125-015-3790-6</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Burckhardt MA, Smith GJ, Cooper MN, et al. Real-world outcomes of insulin pump compared to injection therapy in a population-based sample of children with type 1 diabetes. Pediatr Diabetes. 2018;19(8):1459-1466. doi: https://doi.org/10.1111/pedi.12754</mixed-citation><mixed-citation xml:lang="en">Burckhardt MA, Smith GJ, Cooper MN, et al. Real-world outcomes of insulin pump compared to injection therapy in a population-based sample of children with type 1 diabetes. Pediatr Diabetes. 2018;19(8):1459-1466. doi: https://doi.org/10.1111/pedi.12754</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Витебская А.В., Попович А.В. Причины отказов от помповой инсулинотерапии детей и подростков с сахарным диабетом 1 типа // Поликлиника. — 2016. — №1–2. — С.35–39.</mixed-citation><mixed-citation xml:lang="en">Vitebskaya AV, Popovich AV. Prichiny otkazov ot pompovoj insulinoterapii detej i podrostkov s saharnym diabetom 1 tipa. Poliklinika. 2016;1–2:35–39. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Емельянов А.О., Кураева Т.Л., Лаптев Д.Н., и др. Проспективное наблюдение эффективности и безопасности помповой инсулинотерапии у детей и подростков // Сахарный диабет. — 2010. — Т.13. — №3. — С.143-146. doi: https://doi.org/10.14341/2072-0351-5503</mixed-citation><mixed-citation xml:lang="en">Emel’yanov AO, Kuraeva TL, Laptev DN, et al. Prospective study of efficacy and safety of insulin pump therapy in children and adolescents. Diabetes mellitus. 2010;13(3):143-146. (In Russ.) doi: https://doi.org/10.14341/2072-0351-5503</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">van den Boom L, Karges B, Auzanneau M, et al. Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017. Diabetes Care. 2019;42(11):2050-2056. doi: https://doi.org/10.2337/dc19-0345</mixed-citation><mixed-citation xml:lang="en">van den Boom L, Karges B, Auzanneau M, et al. Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017. Diabetes Care. 2019;42(11):2050-2056. doi: https://doi.org/10.2337/dc19-0345</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Miller KM, Hermann J, Foster N, et al. Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care. 2020;43(1):e1-e2. doi: https://doi.org/10.2337/dc19-1214</mixed-citation><mixed-citation xml:lang="en">Miller KM, Hermann J, Foster N, et al. Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care. 2020;43(1):e1-e2. doi: https://doi.org/10.2337/dc19-1214</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Naranjo D, Tanenbaum ML, Iturralde E, Hood KK. Diabetes Technology: Uptake, Outcomes, Barriers, and the Intersection With Distress. J Diabetes Sci Technol. 2016;10(4):852-858. doi: https://doi.org/10.1177/1932296816650900</mixed-citation><mixed-citation xml:lang="en">Naranjo D, Tanenbaum ML, Iturralde E, Hood KK. Diabetes Technology: Uptake, Outcomes, Barriers, and the Intersection With Distress. J Diabetes Sci Technol. 2016;10(4):852-858. doi: https://doi.org/10.1177/1932296816650900</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Prahalad P, Ebekozien O, Alonso GT, et al. Multi-Clinic Quality Improvement Initiative Increases Continuous Glucose Monitoring Use Among Adolescents and Young Adults With Type 1 Diabetes. Clin Diabetes. 2021;39(3):264-271. doi: https://doi.org/10.2337/cd21-0026</mixed-citation><mixed-citation xml:lang="en">Prahalad P, Ebekozien O, Alonso GT, et al. Multi-Clinic Quality Improvement Initiative Increases Continuous Glucose Monitoring Use Among Adolescents and Young Adults With Type 1 Diabetes. Clin Diabetes. 2021;39(3):264-271. doi: https://doi.org/10.2337/cd21-0026</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Tauschmann M, Forlenza G, Hood K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022;23(8):1390-1405. doi: https://doi.org/10.1111/pedi.13451</mixed-citation><mixed-citation xml:lang="en">Tauschmann M, Forlenza G, Hood K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022;23(8):1390-1405. doi: https://doi.org/10.1111/pedi.13451</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Безлепкина О.Б., Демина Е.С., и др. Результаты клинической апробации системы FreeStyle Libre у детей с сахарным диабетом 1 типа: улучшение гликемического контроля в сочетании со снижением риска тяжелой гипогликемии и диабетического кетоацидоза // Проблемы эндокринологии. — 2022. — Т.68. — №3. — С.86-92. doi: https://doi.org/10.14341/probl12877</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Bezlepkina OB, Demina ES, et al. Evaluation of FreeStyle Libre in pediatric T1DM: improved glycemic control, reduction in diabetic ketoacidosis and severe hypoglycemia. Problems of Endocrinology. 2022;68(3):86-92. (In Russ.) doi: https://doi.org/10.14341/probl12877</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dicembrini I, Cosentino C, Monami M, et al. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2021;58(4):401-410. doi: https://doi.org/10.1007/s00592-020-01589-3</mixed-citation><mixed-citation xml:lang="en">Dicembrini I, Cosentino C, Monami M, et al. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2021;58(4):401-410. doi: https://doi.org/10.1007/s00592-020-01589-3</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Maiorino MI, Signoriello S, Maio A, et al. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2020;43(5):1146-1156. doi: https://doi.org/10.2337/dc19-1459</mixed-citation><mixed-citation xml:lang="en">Maiorino MI, Signoriello S, Maio A, et al. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2020;43(5):1146-1156. doi: https://doi.org/10.2337/dc19-1459</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Tauschmann M, Hermann JM, Freiberg C, et al. Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry. Diabetes Care. 2020;43(3):e40-e42. doi: https://doi.org/10.2337/dc19-1358</mixed-citation><mixed-citation xml:lang="en">Tauschmann M, Hermann JM, Freiberg C, et al. Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry. Diabetes Care. 2020;43(3):e40-e42. doi: https://doi.org/10.2337/dc19-1358</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Cardona-Hernandez R, Schwandt A, Alkandari H, et al. Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET. Diabetes Care. 2021;44(5):1176-1184. doi: https://doi.org/10.2337/dc20-1674</mixed-citation><mixed-citation xml:lang="en">Cardona-Hernandez R, Schwandt A, Alkandari H, et al. Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET. Diabetes Care. 2021;44(5):1176-1184. doi: https://doi.org/10.2337/dc20-1674</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378. doi: https://doi.org/10.1001/jama.2016.19975</mixed-citation><mixed-citation xml:lang="en">Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378. doi: https://doi.org/10.1001/jama.2016.19975</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">von dem Berge T, Remus K, Biester S, et al. In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial. Diabetes Obes Metab. 2022;24(7):1319-1327. doi: https://doi.org/10.1111/dom.14706</mixed-citation><mixed-citation xml:lang="en">von dem Berge T, Remus K, Biester S, et al. In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial. Diabetes Obes Metab. 2022;24(7):1319-1327. doi: https://doi.org/10.1111/dom.14706</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kariyawasam D, Morin C, Casteels K, et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022;4(3):e158-e168. doi: https://doi.org/10.1016/S2589-7500(21)00271-5</mixed-citation><mixed-citation xml:lang="en">Kariyawasam D, Morin C, Casteels K, et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022;4(3):e158-e168. doi: https://doi.org/10.1016/S2589-7500(21)00271-5</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet. 2021;397(10270):208-219. doi: https://doi.org/10.1016/S0140-6736(20)32514-9</mixed-citation><mixed-citation xml:lang="en">Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet. 2021;397(10270):208-219. doi: https://doi.org/10.1016/S0140-6736(20)32514-9</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Deiss D, Irace C, Carlson G, Tweden KS, Kaufman FR. Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol Ther. 2020;22(1):48-52. doi: https://doi.org/10.1089/dia.2019.0159</mixed-citation><mixed-citation xml:lang="en">Deiss D, Irace C, Carlson G, Tweden KS, Kaufman FR. Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol Ther. 2020;22(1):48-52. doi: https://doi.org/10.1089/dia.2019.0159</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ware J, Allen JM, Boughton CK, et al. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022;386(3):209-219. doi: https://doi.org/10.1056/NEJMoa2111673</mixed-citation><mixed-citation xml:lang="en">Ware J, Allen JM, Boughton CK, et al. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022;386(3):209-219. doi: https://doi.org/10.1056/NEJMoa2111673</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Bode B, Carlson A, Liu R, et al. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System. Diabetes Technol Ther. 2021;23(12):828-836. doi: https://doi.org/10.1089/dia.2021.0184</mixed-citation><mixed-citation xml:lang="en">Bode B, Carlson A, Liu R, et al. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System. Diabetes Technol Ther. 2021;23(12):828-836. doi: https://doi.org/10.1089/dia.2021.0184</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Galderisi A, Cohen N, Calhoun P, et al. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care. 2020;43(9):2146-2152. doi: https://doi.org/10.2337/dc20-0091</mixed-citation><mixed-citation xml:lang="en">Galderisi A, Cohen N, Calhoun P, et al. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care. 2020;43(9):2146-2152. doi: https://doi.org/10.2337/dc20-0091</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Sherr JL, Patel NS, Michaud CI, et al. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care. 2016;39(7):1127-1134. doi: https://doi.org/10.2337/dc16-0089</mixed-citation><mixed-citation xml:lang="en">Sherr JL, Patel NS, Michaud CI, et al. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care. 2016;39(7):1127-1134. doi: https://doi.org/10.2337/dc16-0089</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Tsoukas MA, Majdpour D, Yale JF, et al. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. Lancet Digit Health. 2021;3(11):e723-e732. doi: https://doi.org/10.1016/S2589-7500(21)00139-4</mixed-citation><mixed-citation xml:lang="en">Tsoukas MA, Majdpour D, Yale JF, et al. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. Lancet Digit Health. 2021;3(11):e723-e732. doi: https://doi.org/10.1016/S2589-7500(21)00139-4</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Biester T, Muller I, von dem Berge T, et al. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. Diabetes Obes Metab. 2021;23(2):599-608. doi: https://doi.org/10.1111/dom.14258</mixed-citation><mixed-citation xml:lang="en">Biester T, Muller I, von dem Berge T, et al. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. Diabetes Obes Metab. 2021;23(2):599-608. doi: https://doi.org/10.1111/dom.14258</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Haidar A, Rabasa-Lhoret R, Legault L, et al. Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes. J Clin Endocrinol Metab. 2016;101(1):214-223. doi: https://doi.org/10.1210/jc.2015-3003</mixed-citation><mixed-citation xml:lang="en">Haidar A, Rabasa-Lhoret R, Legault L, et al. Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes. J Clin Endocrinol Metab. 2016;101(1):214-223. doi: https://doi.org/10.1210/jc.2015-3003</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Петеркова В.А. Использование телемедицины для улучшения гликемического контроля и качества жизни у детей с сахарным диабетом 1 типа на помповой инсулинотерапии // Сахарный диабет. — 2017. — Т.20. — №6. — С.420-426. doi: https://doi.org/10.14341/DM8677</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Peterkova VA. Use of telemedicine improves glycemic control and quality of life in type 1 diabetes children on insulin pump therapy. Diabetes mellitus. 2017;20(6):420-426. (In Russ.) doi: https://doi.org/10.14341/DM8677</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Емельянов А.О., Самойлова Ю.Г., и др. Дистанционное наблюдение и лечение детей и подростков с сахарным диабетом 1 типа // Проблемы эндокринологии. — 2020. — Т.66. — №4. — С.50-60. doi: https://doi.org/10.14341/probl12201</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Emelyanov AO, Samoilova YG, et al. Remote monitoring and treatment of children and adolescents with type 1 diabetes. Problems of Endocrinology. 2020;66(4):50-60. (In Russ.) doi: https://doi.org/10.14341/probl12201</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Еремина И.А., Карпушкина А.В., и др. Дистанционное наблюдение подростков с сахарным диабетом 1 типа с использованием мобильного приложения // Сахарный диабет. — 2021. — Т.24. — №5. — С.404-413. doi: https://doi.org/10.14341/DM12776</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Eremina IA, Karpushkina AV, et al. Remote monitoring of adolescents with type 1 diabetes mellitus using a mobile application. Diabetes mellitus. 2021;24(5):404-413. (In Russ.) doi: https://doi.org/10.14341/DM12776</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Сорокин Д.Ю., Труфанова Е.С., Реброва О.Ю., и др. Система поддержки принятия врачебных решений на основе искусственного интеллекта для коррекции параметров инсулиновой помпы у детей с сахарным диабетом 1 типа // Сахарный диабет. — 2024. — Т.27. — №3. — С.242-253. doi: https://doi.org/10.14341/DM13167</mixed-citation><mixed-citation xml:lang="en">Sorokin DY, Trufanova ES, Rebrova OY, et al. Clinical decision support system based on artificial intelligence for adjusting insulin pump parameters in children with type 1 diabetes mellitus. Diabetes mellitus. 2024;27(3):242-253. (In Russ.) doi: https://doi.org/10.14341/DM13167</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Сорокин Д.Ю., Труфанова Е.С., и др. Рандомизированное контролируемое испытание эффективности и безопасности системы поддержки принятия врачебных решений на основе искусственного интеллекта для коррекции параметров инсулиновой помпы у детей с сахарным диабетом 1 типа // Сахарный диабет. — 2024. — Т.27. — №3. — С.254-264. doi: https://doi.org/10.14341/DM13171</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Sorokin DY, Trufanova ES, et al. Effectiveness and safety of an artificial intelligence-based medical decision support system for adjusting insulin pump settings in children with type 1 diabetes mellitus: randomized controlled trial. Diabetes mellitus. 2024;27(3):254-264. (In Russ.) doi: https://doi.org/10.14341/DM13171</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
